[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1952


Author Affiliations

From the Division of Ophthalmology, Department of Surgery, Stanford University School of Medicine, and the Veterans Administration Hospital.

AMA Arch Ophthalmol. 1952;47(6):787-797. doi:10.1001/archopht.1952.01700030806009

THE OBSERVATION that the hormone cortisone exerts a remarkable therapeutic effect on certain inflammations of the eye is one of the most important contributions to ophthalmologic therapy in a decade which has witnessed many revolutionary discoveries. The further observation that this hormone is effective by local application, topically, subconjunctivally, or by retrobulbar injection, has already made its use more widespread in ophthalmology than in any other branch of medicine. In its local application the many hazardous metabolic side-effects are avoided, since the dose required is minute as compared with that required for its systemic administration. For the same reason, the temporary scarcity of the drug has not limited its use in the eye to the same extent that it has in other fields.

Leopold and his co-workers1 have confirmed experimentally what was already quite certain clinically, namely, that cortisone applied locally penetrates the eye to produce therapeutic concentrations in

First Page Preview View Large
First page PDF preview
First page PDF preview